ReviewCardiovascular diabetology2017
Updates on cardiovascular outcome trials in diabetes.
Review in Cardiovascular diabetology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017.Cardiovascular diabetology · 2018Pooled it
- Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16).Applied health economics and health policy · 2019Trial
- Obesity, diabetes mellitus, and cardiometabolic risk: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2023.Obesity pillars · 2023Article
- SGLT1: A Potential Drug Target for Cardiovascular Disease.Drug design, development and therapy · 2023Review
- The Effects of Glucose Lowering Agents on the Secondary Prevention of Coronary Artery Disease in Patients with Type 2 Diabetes.Endocrinology and metabolism (Seoul, Korea) · 2021Article
- Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2019Article
- Marginal hazard ratio estimates in joint frailty models for heart failure trials.Biometrical journal. Biometrische Zeitschrift · 2019Article
- Cardiovascular Outcome Trials in Type 2 Diabetes: What Do They Mean for Clinical Practice?Clinical diabetes : a publication of the American Diabetes Association · 2019Article
- Cardiovascular disease prevalence and risk factor prevalence in Type 2 diabetes: a contemporary analysis.Diabetic medicine : a journal of the British Diabetic Association · 2019Article
- The Unique Pharmacological and Pharmacokinetic Profile of Teneligliptin: Implications for Clinical Practice.Drugs · 2019Review
- Report from the 4th Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group.Cardiovascular diabetology · 2019Article
- Consensus recommendations for management of patients with type 2 diabetes mellitus and cardiovascular diseases.Diabetology & metabolic syndrome · 2019Review
- Persistence to Treatment with Novel Antidiabetic Drugs (Dipeptidyl Peptidase-4 Inhibitors, Sodium-Glucose Co-Transporter-2 Inhibitors, and Glucagon-Like Peptide-1 Receptor Agonists) in People with Type 2 Diabetes: A Nationwide Cohort Study.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2018Article
- Comparative cardiovascular outcomes in the era of novel anti-diabetic agents: a comprehensive network meta-analysis of 166,371 participants from 170 randomized controlled trials.Cardiovascular diabetology · 2018Review
- Unexplained reciprocal regulation of diabetes and lipoproteins.Current opinion in lipidology · 2018Review
- Molecular and clinical roles of incretin-based drugs in patients with heart failure.Heart failure reviews · 2018Review
- Report from the 3rd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group.Cardiovascular diabetology · 2018Article
- Relationship between polyunsaturated fatty acid composition in serum phospholipids, systemic low-grade inflammation, and glycemic control in patients with type 2 diabetes and atherosclerotic cardiovascular disease.Cardiovascular diabetology · 2018Article
- Correction to: Updates on cardiovascular outcome trials in diabetes.Cardiovascular diabetology · 2017Article
- Update on Management of Type 2 Diabetes for Cardiologists.Methodist DeBakey cardiovascular journalReview
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 2008 the Food and Drug Administration introduced a guidance for industry that requires the investigation of cardiovascular outcomes of glucose-lowering medications. Since then, an increasing number of cardiovascular outcome trials have been completed in diabetes patients with high cardiovascular risk for members of the SGLT-2 and DPP4 inhibitors and GLP-1 receptor agonist classes. The trials confirmed cardiovascular safety for all tested anti-hyperglycaemic drugs and, in addition empagliflozin, semaglutide and liraglutide could even reduce cardiovascular risk. The present review summarizes the results of the DEVOTE, CANVAS, EXSCEL and ACE trials that tested cardiovascular safety of Insulin degludec, canagliflozin, once-weekly exenatide and acarbose and were published in 2017. We provide context on these results by comparing them with earlier trials of glucose-lowering drugs and give an outlook on what to expect in coming years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.